A new study revealed that Fedratinib demonstrated reduction in spleen size and lower symptom burden in patients with myelofibrosis: https://t.co/HVReq6HStK
We are pleased to announce we will be presenting the first preclinical data for our LockBody® program in a poster at #ASCO22. Come see us today at 8-11 AM Central Time virtually and in-person in Hall A, Poster #217. Read the full release here: https://t.co/e3azEcDR7k
We are delighted to announce an exciting new collaboration with @BioNTech_Group to develop novel immunotherapies for cancer and other diseases.
We look forward to working together to further leverage our Humabody® VH platform within mRNA therapeutics.
https://t.co/4SZrqfuqLg
When we started our work at UH8, we had no idea just how exciting and fascinating it was going to get. Now we do. Maximal potency, minimised tox, easy dosing format. https://t.co/ftEI7TS5le @MedicxiKevin@medicxi@MadMabScientist#cancer#nextgeneration
Today, we're pleased to announce positive topline data from the Phase 2a part of our proof-of-concept study evaluating SerpinPC in severe #hemophilia A and B patients. Read more here: https://t.co/EvOE9CXuyw $CNTA
It is indeed a brilliant achievement Gil. Bravo Kate, I do believe the best measure of a persons worth is whether you’ve made the world a better place @mavenclinic
I’m incredibly proud of AstraZeneca’s Operations team and the tremendous work they’ve done to deliver a billion doses of our COVID-19 vaccine. The inside story of the Oxford AstraZeneca vaccine: meet the man who made it
https://t.co/swERUMhwRb
Israel presents: How vaccines beat COVID-19 (for now)
Since mid-Jan peak:
99% fewer cases (now ~5 daily cases per million)
98% fewer critically ill (now ~0.4 daily per million)
98% fewer deaths (now ~0.2 daily per million)
Life is back to normal, very few restrictions remain
To all the people involved with the Oxford AZ vaccine effort, please don't be disheartened by all this misinformation and shameful political nonsense. You're leading the way out of this pandemic and your colleagues in the industry are proud of you.